Trial Profile
A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- 24 May 2021 Results assessing efficacy and safety of brentuximab vedotin in patients with relapsed/refractory germ cell tumors, published in the Investigational New Drugs.
- 03 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 30 Mar 2019 Status changed from recruiting to active, no longer recruiting.